A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.
In the UK, over 250 000 patients take continuous oral glucocorticoids (GCs), yet no more than 14% receive any therapy to prevent bone loss, a major complication of GC treatment. Bone loss is rapid, particularly in the first year, and fracture risk may double. This review, based wherever possible on clinical evidence, aims to provide easy-to-use guidance with wide applicability. A treatment algorithm is presented for adults receiving GC doses of 7.5 mg day(-1) or more for 6 months or more. General measures, e.g. alternative GCs and routes of administration, and therapeutic interventions, e.g. cyclical etidronate and hormone replacement, are recommended.
Eastell
R
R
University of Sheffield Medical School, UK. r.eastell@sheffield.ac.uk
Reid
D M
DM
Compston
J
J
Cooper
C
C
Fogelman
I
I
Francis
R M
RM
Hosking
D J
DJ
Purdie
D W
DW
Ralston
S H
SH
Reeve
J
J
Russell
R G
RG
Stevenson
J C
JC
Torgerson
D J
DJ
D001862:Bone Resorption / Q000139:chemically induced; D002116:Calcitonin / Q000627:therapeutic use; D002117:Calcitriol / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use; D017850:Economics, Pharmaceutical; D005459:Fluorides / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects*; D020249:Hormone Replacement Therapy; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control / Q000628:therapy; D006113:United Kingdom; D014807:Vitamin D / Q000627:therapeutic use
D004164:Diphosphonates; D005938:Glucocorticoids; D014807:Vitamin D; D002116:Calcitonin; D002117:Calcitriol; D005459:Fluorides